MX2017001898A - Peptidos que contienen manosa-6-fosfato fusionados a enzimas lisosomales. - Google Patents
Peptidos que contienen manosa-6-fosfato fusionados a enzimas lisosomales.Info
- Publication number
- MX2017001898A MX2017001898A MX2017001898A MX2017001898A MX2017001898A MX 2017001898 A MX2017001898 A MX 2017001898A MX 2017001898 A MX2017001898 A MX 2017001898A MX 2017001898 A MX2017001898 A MX 2017001898A MX 2017001898 A MX2017001898 A MX 2017001898A
- Authority
- MX
- Mexico
- Prior art keywords
- mannose
- lysosomal enzymes
- bearing peptides
- peptides fused
- lysosomal
- Prior art date
Links
- 230000002132 lysosomal effect Effects 0.000 title abstract 3
- 102000004190 Enzymes Human genes 0.000 title abstract 2
- 108090000790 Enzymes Proteins 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical group OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 208000015439 Lysosomal storage disease Diseases 0.000 abstract 1
- 230000004988 N-glycosylation Effects 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1288—Transferases for other substituted phosphate groups (2.7.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/08—Transferases for other substituted phosphate groups (2.7.8)
- C12Y207/08017—UDP-N-acetylglucosamine--lysosomal-enzyme N-acetylglucosaminephosphotransferase (2.7.8.17)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Marine Sciences & Fisheries (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462036082P | 2014-08-11 | 2014-08-11 | |
| PCT/US2015/044713 WO2016025519A1 (en) | 2014-08-11 | 2015-08-11 | Mannose-6-phosphate bearing peptides fused to lysosomal enzymes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017001898A true MX2017001898A (es) | 2017-04-11 |
Family
ID=54035297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017001898A MX2017001898A (es) | 2014-08-11 | 2015-08-11 | Peptidos que contienen manosa-6-fosfato fusionados a enzimas lisosomales. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10722559B2 (enExample) |
| EP (1) | EP3185889B1 (enExample) |
| JP (1) | JP6623213B2 (enExample) |
| CN (1) | CN106573039A (enExample) |
| AU (1) | AU2015301809A1 (enExample) |
| BR (1) | BR112017002741A2 (enExample) |
| CA (1) | CA2956469A1 (enExample) |
| EA (1) | EA201790178A1 (enExample) |
| MX (1) | MX2017001898A (enExample) |
| WO (1) | WO2016025519A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2588130T3 (pl) | 2010-06-25 | 2017-09-29 | Shire Human Genetic Therapies, Inc. | Dostarczanie środków terapeutycznych do OUN |
| US20220133863A1 (en) * | 2010-06-25 | 2022-05-05 | Shire Human Genetic Therapies, Inc. | Treatment of sanfilippo syndrome type b |
| CR20200129A (es) | 2017-10-02 | 2020-08-22 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas |
| WO2020028864A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| BR112021012113A2 (pt) * | 2018-12-19 | 2021-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | Moléculas bifuncionais para direcionamento lisossomal e composições e métodos relacionados |
| BR112021026866A2 (pt) * | 2019-07-02 | 2022-03-03 | M6P Therapeutics | Composições de vetor e métodos de seu uso para o tratamento de distúrbios do armazenamento lisossômico |
| CN111455004B (zh) * | 2020-02-29 | 2023-05-05 | 浙江农林大学 | 一种脂肪酶催化在线合成香豆素-3-羧酸-6’-o-d-甘露糖酯的方法 |
| US20230211001A1 (en) * | 2020-07-30 | 2023-07-06 | The Board Of Trustees Of The Leland Stanford Junior University | Lysosomal Targeting Molecules Comprising Knottin Peptides And Related Compositions And Methods |
| CA3226269A1 (en) | 2021-07-14 | 2023-01-19 | Lycia Therapeutics, Inc. | Asgpr cell surface receptor binding compounds and conjugates |
| WO2023150387A1 (en) * | 2022-02-07 | 2023-08-10 | M6P Therapeutics, Inc. | Compositions comprising acid alpha glucosidase and methods of use thereof |
| JP2025512464A (ja) | 2022-04-15 | 2025-04-17 | ダイン セラピューティクス，インコーポレーテッド | 筋緊張性ジストロフィーを処置するための筋標的化複合体および製剤 |
| WO2025238106A1 (en) * | 2024-05-15 | 2025-11-20 | M6P Therapeutics (Switzerland) GmbH | Lysosome-targeting degradation fusion design |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040142474A1 (en) * | 2000-09-14 | 2004-07-22 | Expression Genetics, Inc. | Novel cationic lipopolymer as a biocompatible gene delivery agent |
| US7560424B2 (en) * | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| EP2399586A1 (en) * | 2002-01-11 | 2011-12-28 | Jefferies, Dr., Wilfred | Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes |
| US20110027267A1 (en) * | 2007-11-09 | 2011-02-03 | Anaphore, Inc. | Fusion Proteins of Mannose Binding Lectins for Treatment of Disease |
| DK2279210T3 (en) * | 2008-05-07 | 2017-07-24 | Biomarin Pharm Inc | Lysosomal targeting peptides and uses thereof |
| ES2643015T3 (es) | 2010-06-25 | 2017-11-21 | Shire Human Genetic Therapies, Inc. | Tratamiento del Síndrome de Sanfilippo Tipo B |
| RU2626514C2 (ru) * | 2010-06-25 | 2017-07-28 | Шир Хьюман Дженетик Терапис, Инк. | Доставка к цнс лечебных агентов |
| EP2975134A3 (en) | 2010-07-22 | 2016-02-24 | Shire Human Genetic Therapies, Inc. | Crystal structure of human alpha-n-acetylglucosaminidase |
| JP5959114B2 (ja) | 2011-05-19 | 2016-08-02 | 学校法人 明治薬科大学 | リン酸化糖鎖を含有する組換えヒトサポシンｂタンパク質及びその用途 |
| WO2012166653A2 (en) * | 2011-05-27 | 2012-12-06 | Callidus Biopharma, Inc. | Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases |
| CN103958676A (zh) * | 2011-10-12 | 2014-07-30 | 辛那杰瓦生物制药股份有限公司 | 重组人naglu蛋白质及其用途 |
| BR112015012152B1 (pt) * | 2012-11-27 | 2023-04-25 | Biomarin Pharmaceutical Inc | Proteína de fusão terapêutica direcionada que compreende uma enzima lisossomal, ácido nucleico, composição farmacêutica, método para produzir a dita proteína e usos da proteína para tratar uma doença de armazenamento lisossomal e mucopolissacaridose tipo iiib |
-
2015
- 2015-08-11 EP EP15757368.4A patent/EP3185889B1/en active Active
- 2015-08-11 CA CA2956469A patent/CA2956469A1/en not_active Abandoned
- 2015-08-11 CN CN201580043154.1A patent/CN106573039A/zh active Pending
- 2015-08-11 MX MX2017001898A patent/MX2017001898A/es unknown
- 2015-08-11 WO PCT/US2015/044713 patent/WO2016025519A1/en not_active Ceased
- 2015-08-11 US US15/503,223 patent/US10722559B2/en active Active
- 2015-08-11 JP JP2017507791A patent/JP6623213B2/ja active Active
- 2015-08-11 BR BR112017002741-0A patent/BR112017002741A2/pt not_active Application Discontinuation
- 2015-08-11 AU AU2015301809A patent/AU2015301809A1/en not_active Abandoned
- 2015-08-11 EA EA201790178A patent/EA201790178A1/ru unknown
-
2020
- 2020-06-18 US US16/904,943 patent/US20200376095A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017529326A (ja) | 2017-10-05 |
| EP3185889A1 (en) | 2017-07-05 |
| CN106573039A (zh) | 2017-04-19 |
| US20200376095A1 (en) | 2020-12-03 |
| WO2016025519A1 (en) | 2016-02-18 |
| BR112017002741A2 (pt) | 2018-02-27 |
| EA201790178A1 (ru) | 2017-07-31 |
| AU2015301809A1 (en) | 2017-02-02 |
| JP6623213B2 (ja) | 2019-12-18 |
| CA2956469A1 (en) | 2016-02-18 |
| US10722559B2 (en) | 2020-07-28 |
| US20170232076A1 (en) | 2017-08-17 |
| EP3185889B1 (en) | 2020-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017001898A (es) | Peptidos que contienen manosa-6-fosfato fusionados a enzimas lisosomales. | |
| MX367024B (es) | Proteinas de fusion de enzima lisosomal terapeutica objetivo y usos de las mismas. | |
| ZA202002094B (en) | Trispecific proteins and methods of use | |
| MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
| PH12019550261A1 (en) | Compositions and methods for internalizing enzymes | |
| WO2012135805A3 (en) | Delivery and formulation of engineered nucleic acids | |
| EA201591281A1 (ru) | Рибонуклеиновые кислоты с 4'-тиомодифицированными нуклеотидами и связанные с ними способы | |
| BR112016002753A2 (pt) | anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos | |
| MX2016001317A (es) | Variantes de enzimas. | |
| WO2012019168A3 (en) | Engineered nucleic acids and methods of use thereof | |
| MX338426B (es) | Enzima de enfermedad del almacenamiento lisosomico. | |
| PH12017501501A1 (en) | Compositions and methods for inhibiting expression of tmprss6 gene | |
| NZ743008A (en) | Compositions and methods for internalizing enzymes | |
| MX2017011004A (es) | Inclusion del exon2 inducida por antisentido en alfa-glucosidasa.acida. | |
| EP4332576A3 (en) | Synergistic enhancement of the delivery of nucleic acids via blended formulations | |
| CO6700848A2 (es) | Formulaciones recubiertas entéricas de pancrelipilasa, de baja intensidad | |
| MX2022014532A (es) | Metodo para seleccionar proteinas recombinantes ricas en m6p. | |
| MX359953B (es) | Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada. | |
| MX2014004359A (es) | Proteina naglu humana recombinante y usos de la misma. | |
| MX390894B (es) | Polipéptido de fusión anti-cáncer. | |
| BR112013001753A2 (pt) | método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada. | |
| EA201991409A3 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
| MX2018010196A (es) | Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas. | |
| HK1222325A1 (zh) | 高效的胰酶藥物組合物 | |
| WO2011156641A3 (en) | Microneedle arrays for active agent delivery |